Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors

Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma.

Read more